Top Page
China Traditional Chinese Medicine Holdings Co
(OTC:0570)
China Traditional Chinese Medicine Holdings Co (0570) vs. iShares MSCI Hong Kong ETF (EWH)
China Traditional Chinese Medicine Holdings Co Business Overview & Revenue Model
China Traditional Chinese Medicine Holdings Co Financial Statement Overview
| Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 16.51B | 18.12B | 14.30B | 19.05B | 14.81B |
| Gross Profit | 7.86B | 9.27B | 7.20B | 11.83B | 9.13B |
| EBITDA | 1.82B | 2.56B | 2.16B | 3.59B | 3.16B |
| Net Income | 54.07M | 1.29B | 764.49M | 1.93B | 1.66B |
Balance Sheet | |||||
| Total Assets | 35.06B | 37.07B | 35.62B | 36.39B | 33.09B |
| Cash, Cash Equivalents and Short-Term Investments | 5.34B | 3.69B | 3.67B | 4.14B | 5.03B |
| Total Debt | 4.02B | 5.16B | 5.04B | 5.06B | 5.22B |
| Total Liabilities | 11.13B | 13.13B | 12.67B | 13.73B | 12.19B |
| Stockholders Equity | 21.20B | 21.16B | 20.17B | 19.72B | 18.06B |
Cash Flow | |||||
| Free Cash Flow | 2.07B | 680.20M | 565.09M | -81.17M | -1.02B |
| Operating Cash Flow | 2.58B | 1.17B | 1.09B | 796.03M | 228.47M |
| Investing Cash Flow | -379.24M | -477.62M | -374.15M | -536.94M | -1.07B |
| Financing Cash Flow | -1.39B | -584.31M | -557.28M | -724.32M | -1.01B |
China Traditional Chinese Medicine Holdings Co Technical Analysis
China Traditional Chinese Medicine Holdings Co Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
75 Outperform | HK$13.31B | 12.37 | 22.22% | 3.94% | 19.05% | 13.68% | |
73 Outperform | HK$6.16B | 6.90 | 11.25% | 6.20% | -20.64% | -25.39% | |
70 Outperform | HK$9.90B | 10.63 | ― | 4.20% | 2.32% | -14.41% | |
55 Neutral | HK$13.72B | -154.74 | -4.96% | 0.74% | 19.21% | -115.91% | |
54 Neutral | $11.99B | 197.41 | -1.26% | 3.29% | -9.58% | -128.83% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
China Traditional Chinese Medicine Holdings Co Corporate Events
China Traditional Chinese Medicine Holdings Co. Limited announced that its subsidiary, Tongjitang Pharmaceutical, has entered into agreements for the construction of an alcohol extraction workshop. The project involves purification engineering and wastewater pretreatment, with services provided by Pharmengin and Wuhan Hongli. These agreements are considered connected transactions under the Hong Kong Stock Exchange Listing Rules, as Pharmengin is a subsidiary of CNPGC, a major shareholder of the company. The transactions are exempt from independent shareholder approval but require announcement and reporting due to their size.
The most recent analyst rating on (HK:0570) stock is a Hold with a HK$2.50 price target. To see the full list of analyst forecasts on China Traditional Chinese Medicine Holdings Co stock, see the HK:0570 Stock Forecast page.
China Traditional Chinese Medicine Holdings Co. Limited reported a decline in revenue and profit for the first half of 2025, with total revenue dropping by 11% and a net loss of RMB 141.76 million compared to a profit in the previous year. The decrease in revenue was observed across most product lines, with the most significant drop in the Chinese medicinal herbs integration business. This downturn reflects challenges in the TCM market and may impact the company’s strategic positioning and stakeholder relations.
The most recent analyst rating on (HK:0570) stock is a Hold with a HK$2.50 price target. To see the full list of analyst forecasts on China Traditional Chinese Medicine Holdings Co stock, see the HK:0570 Stock Forecast page.
China Traditional Chinese Medicine Holdings Co. Limited announced that its board of directors will meet on August 29, 2025, to consider and approve the interim results for the first half of 2025. This meeting could have implications for the company’s financial performance and market positioning, potentially affecting stakeholders’ perspectives.
The most recent analyst rating on (HK:0570) stock is a Buy with a HK$5.00 price target. To see the full list of analyst forecasts on China Traditional Chinese Medicine Holdings Co stock, see the HK:0570 Stock Forecast page.
China Traditional Chinese Medicine Holdings Co. Limited has appointed Mr. Peng Li as an executive director and a member of the strategic committee, effective July 25, 2025. Mr. Peng brings extensive experience in traditional Chinese medicine and leadership roles within the healthcare sector, which is expected to bolster the company’s strategic direction and operational expertise.
The most recent analyst rating on (HK:0570) stock is a Buy with a HK$5.00 price target. To see the full list of analyst forecasts on China Traditional Chinese Medicine Holdings Co stock, see the HK:0570 Stock Forecast page.
China Traditional Chinese Medicine Holdings Co. Limited has announced the composition of its board of directors, detailing the roles and functions of each member. This organizational update provides insights into the company’s governance structure, which may influence its strategic decisions and operational effectiveness, potentially impacting stakeholders’ interests and the company’s positioning in the traditional medicine industry.
The most recent analyst rating on (HK:0570) stock is a Buy with a HK$5.00 price target. To see the full list of analyst forecasts on China Traditional Chinese Medicine Holdings Co stock, see the HK:0570 Stock Forecast page.
China Traditional Chinese Medicine Holdings Co. Limited has issued a profit warning, indicating an expected decline in net profit by 165% to 175% for the first half of 2025 compared to the previous year. The decline is attributed to reduced revenue and profitability in its concentrated TCM granules business due to increased centralized procurement and market competition, as well as a provision for goodwill impairment. This impairment is non-cash and aims to position the company for future improvements, with the expectation that profit would decrease by 50% to 60% without the impairment effect.
The most recent analyst rating on (HK:0570) stock is a Buy with a HK$5.00 price target. To see the full list of analyst forecasts on China Traditional Chinese Medicine Holdings Co stock, see the HK:0570 Stock Forecast page.
China Traditional Chinese Medicine Holdings Co. Limited announced that the resolution to appoint BDO as the auditor of the company was passed at the Extraordinary General Meeting held on 18 July 2025. The resolution received unanimous support from shareholders, indicating strong backing for the company’s governance decisions and potentially reinforcing investor confidence.
The most recent analyst rating on (HK:0570) stock is a Hold with a HK$4.60 price target. To see the full list of analyst forecasts on China Traditional Chinese Medicine Holdings Co stock, see the HK:0570 Stock Forecast page.
China Traditional Chinese Medicine Holdings Co. Limited has announced an extraordinary general meeting scheduled for July 18, 2025, to appoint BDO as the company’s auditor and authorize the board to fix the auditor’s remuneration. This meeting is significant for stakeholders as it involves key decisions regarding the company’s financial oversight, potentially impacting its governance and operational transparency.
The most recent analyst rating on (HK:0570) stock is a Buy with a HK$5.00 price target. To see the full list of analyst forecasts on China Traditional Chinese Medicine Holdings Co stock, see the HK:0570 Stock Forecast page.
China Traditional Chinese Medicine Holdings Co. Limited announced that all resolutions proposed at its Annual General Meeting on June 27, 2025, were approved by shareholders. This includes the approval of financial statements, the declaration of dividends, and the re-election of directors, reflecting strong shareholder support and stable governance, which may positively impact the company’s market position and stakeholder confidence.
The most recent analyst rating on (HK:0570) stock is a Buy with a HK$5.00 price target. To see the full list of analyst forecasts on China Traditional Chinese Medicine Holdings Co stock, see the HK:0570 Stock Forecast page.